Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States

The rapid development of commercially available molecular assays in response to the COVID-19 pandemic has been essential in identifying positive cases and guiding state and national response plans. With over 200 SARS-CoV-2 molecular tests having received emergency use authorization by the US Food an...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Michelle R., Binnicker, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858713/
https://www.ncbi.nlm.nih.gov/pubmed/35636818
http://dx.doi.org/10.1016/j.cll.2022.02.001
_version_ 1784654295335960576
author Campbell, Michelle R.
Binnicker, Matthew J.
author_facet Campbell, Michelle R.
Binnicker, Matthew J.
author_sort Campbell, Michelle R.
collection PubMed
description The rapid development of commercially available molecular assays in response to the COVID-19 pandemic has been essential in identifying positive cases and guiding state and national response plans. With over 200 SARS-CoV-2 molecular tests having received emergency use authorization by the US Food and Drug Administration, numerous studies have been conducted to evaluate these methods and compare their analytical and clinical performance. By applying the lessons learned from the rapid development of molecular assays in response to the COVID-19 pandemic, the diagnostic industry will be better prepared to respond to future outbreaks of novel infectious diseases.
format Online
Article
Text
id pubmed-8858713
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-88587132022-02-22 Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States Campbell, Michelle R. Binnicker, Matthew J. Clin Lab Med Article The rapid development of commercially available molecular assays in response to the COVID-19 pandemic has been essential in identifying positive cases and guiding state and national response plans. With over 200 SARS-CoV-2 molecular tests having received emergency use authorization by the US Food and Drug Administration, numerous studies have been conducted to evaluate these methods and compare their analytical and clinical performance. By applying the lessons learned from the rapid development of molecular assays in response to the COVID-19 pandemic, the diagnostic industry will be better prepared to respond to future outbreaks of novel infectious diseases. Elsevier Inc. 2022-06 2022-02-21 /pmc/articles/PMC8858713/ /pubmed/35636818 http://dx.doi.org/10.1016/j.cll.2022.02.001 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Campbell, Michelle R.
Binnicker, Matthew J.
Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States
title Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States
title_full Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States
title_fullStr Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States
title_full_unstemmed Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States
title_short Analytic and Clinical Performance of Major Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Assays in the United States
title_sort analytic and clinical performance of major commercial severe acute respiratory syndrome coronavirus 2 molecular assays in the united states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858713/
https://www.ncbi.nlm.nih.gov/pubmed/35636818
http://dx.doi.org/10.1016/j.cll.2022.02.001
work_keys_str_mv AT campbellmicheller analyticandclinicalperformanceofmajorcommercialsevereacuterespiratorysyndromecoronavirus2molecularassaysintheunitedstates
AT binnickermatthewj analyticandclinicalperformanceofmajorcommercialsevereacuterespiratorysyndromecoronavirus2molecularassaysintheunitedstates

Ejemplares similares